[go: up one dir, main page]

MX2018009395A - Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados. - Google Patents

Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados.

Info

Publication number
MX2018009395A
MX2018009395A MX2018009395A MX2018009395A MX2018009395A MX 2018009395 A MX2018009395 A MX 2018009395A MX 2018009395 A MX2018009395 A MX 2018009395A MX 2018009395 A MX2018009395 A MX 2018009395A MX 2018009395 A MX2018009395 A MX 2018009395A
Authority
MX
Mexico
Prior art keywords
compositions
cleavage sites
influenza hemagglutinin
heterologous epitopes
maturation cleavage
Prior art date
Application number
MX2018009395A
Other languages
English (en)
Other versions
MX380837B (es
Inventor
Luo Chun
Original Assignee
Cg Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cg Discovery Inc filed Critical Cg Discovery Inc
Priority claimed from PCT/US2017/016251 external-priority patent/WO2017136575A1/en
Publication of MX2018009395A publication Critical patent/MX2018009395A/es
Publication of MX380837B publication Critical patent/MX380837B/es

Links

Classifications

    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03H—IMPEDANCE NETWORKS, e.g. RESONANT CIRCUITS; RESONATORS
    • H03H7/00—Multiple-port networks comprising only passive electrical elements as network components
    • H03H7/01—Frequency selective two-port networks
    • H03H7/0115—Frequency selective two-port networks comprising only inductors and capacitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F1/00—Details of amplifiers with only discharge tubes, only semiconductor devices or only unspecified devices as amplifying elements
    • H03F1/02—Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation
    • H03F1/0205—Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation in transistor amplifiers
    • H03F1/0211—Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation in transistor amplifiers with control of the supply voltage or current
    • H03F1/0216—Continuous control
    • H03F1/0222—Continuous control by using a signal derived from the input signal
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F1/00—Details of amplifiers with only discharge tubes, only semiconductor devices or only unspecified devices as amplifying elements
    • H03F1/56—Modifications of input or output impedances, not otherwise provided for
    • H03F1/565—Modifications of input or output impedances, not otherwise provided for using inductive elements
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/189—High-frequency amplifiers, e.g. radio frequency amplifiers
    • H03F3/19—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only
    • H03F3/193—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only with field-effect devices
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/189—High-frequency amplifiers, e.g. radio frequency amplifiers
    • H03F3/19—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only
    • H03F3/195—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only in integrated circuits
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/005—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission adapting radio receivers, transmitters andtransceivers for operation on two or more bands, i.e. frequency ranges
    • H04B1/0064—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission adapting radio receivers, transmitters andtransceivers for operation on two or more bands, i.e. frequency ranges with separate antennas for the more than one band
    • H10W20/496—
    • H10W20/497—
    • H10W44/20—
    • H10W72/00—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/294—Indexing scheme relating to amplifiers the amplifier being a low noise amplifier [LNA]
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/408—Indexing scheme relating to amplifiers the output amplifying stage of an amplifier comprising three power stages
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/451—Indexing scheme relating to amplifiers the amplifier being a radio frequency amplifier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Power Engineering (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Plant Pathology (AREA)

Abstract

Se describen formas modificadas de la proteína de hemaglutinina (HA) que incluyen aquellas con regiones inmunodominantes modificadas y con sitios de segmentación de maduración modificadas, y virus y partículas similares a virus que las contienen.
MX2018009395A 2016-02-03 2017-02-02 Composiciones de hemaglutinina de influenza con epítopos heterólogos y/o sitios de segmentación de maduración alterados. MX380837B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290894P 2016-02-03 2016-02-03
PCT/US2017/016251 WO2017136575A1 (en) 2016-02-03 2017-02-02 Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites

Publications (2)

Publication Number Publication Date
MX2018009395A true MX2018009395A (es) 2018-11-09
MX380837B MX380837B (es) 2025-03-12

Family

ID=63036971

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009395A MX380837B (es) 2016-02-03 2017-02-02 Composiciones de hemaglutinina de influenza con epítopos heterólogos y/o sitios de segmentación de maduración alterados.
MX2021003392A MX2021003392A (es) 2016-02-03 2018-08-01 Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003392A MX2021003392A (es) 2016-02-03 2018-08-01 Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados.

Country Status (10)

Country Link
US (3) US10291197B2 (es)
EP (1) EP3411712B1 (es)
JP (2) JP7560938B2 (es)
KR (1) KR102748840B1 (es)
CN (2) CN109073639B (es)
AU (1) AU2017215345B2 (es)
CA (1) CA3012703A1 (es)
MX (2) MX380837B (es)
RU (2) RU2022108149A (es)
SG (2) SG10202108573TA (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102465833B1 (ko) 2017-11-28 2022-11-11 삼성전자주식회사 무선 통신 시스템에서 전력 설정 방법 및 이를 위한 장치
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
CN117534739B (zh) * 2022-07-15 2024-07-05 中山大学·深圳 一种季节性甲型流感通用Mosaic重组抗原及其疫苗和应用
CN116874607B (zh) * 2023-06-09 2024-12-10 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN118978590B (zh) * 2024-10-12 2025-01-21 北京溯本源和生物科技有限公司 一种利用重组流感病毒免疫小鼠制备杂交瘤单抗的方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
DE10248301A1 (de) * 2002-10-16 2004-04-29 Philipps-Universität Marburg Herstellung eines Lebend-Impfstoffes gegen Influenza-Viren
DE10249294A1 (de) * 2002-10-22 2004-05-13 Rohmax Additives Gmbh Stabile Polymerdispersionen und Verfahren zur Herstellung
CA2695399C (en) * 2007-08-02 2017-10-17 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
JP2011528222A (ja) 2008-07-18 2011-11-17 アイディー バイオメディカル コーポレイション オブ ケベック キメラ呼吸器合胞体ウイルスポリペプチド抗原
ES2593277T3 (es) * 2008-07-18 2016-12-07 Medicago Inc. Nuevo epítopo de inmunización contra el virus de la influenza
BRPI1015053A2 (pt) * 2009-06-24 2019-07-09 Medicago Inc partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
CN101857872A (zh) * 2010-04-06 2010-10-13 浙江省医学科学院 甲型流感病毒抗原决定区更换方法
AU2011360572B2 (en) * 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CN108164602A (zh) * 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
EP3805254A1 (en) * 2013-08-03 2021-04-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
WO2016205347A1 (en) * 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
KR20180115717A (ko) 2018-10-23
CN109073639A (zh) 2018-12-21
EP3411712A1 (en) 2018-12-12
EP3411712C0 (en) 2025-11-19
CN114634916B (zh) 2024-12-20
EP3411712B1 (en) 2025-11-19
BR112018015765A2 (pt) 2019-02-05
US20190341901A1 (en) 2019-11-07
US11206005B2 (en) 2021-12-21
RU2018131243A3 (es) 2020-11-13
SG11201806567WA (en) 2018-08-30
KR102748840B1 (ko) 2025-01-02
MX380837B (es) 2025-03-12
US11979133B2 (en) 2024-05-07
US10291197B2 (en) 2019-05-14
EP3411712A4 (en) 2019-12-04
AU2024200382A1 (en) 2024-03-07
AU2017215345B2 (en) 2023-10-19
RU2018131243A (ru) 2020-03-03
MX2021003392A (es) 2021-05-27
CA3012703A1 (en) 2017-08-10
JP2019506168A (ja) 2019-03-07
RU2769406C2 (ru) 2022-03-31
CN114634916A (zh) 2022-06-17
CN109073639B (zh) 2022-04-01
JP7560938B2 (ja) 2024-10-03
JP7577101B2 (ja) 2024-11-01
US20220200559A1 (en) 2022-06-23
AU2017215345A1 (en) 2018-08-16
SG10202108573TA (en) 2021-09-29
US20180334479A1 (en) 2018-11-22
JP2023024998A (ja) 2023-02-21
RU2022108149A (ru) 2022-05-05

Similar Documents

Publication Publication Date Title
WO2017136575A8 (en) Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
MX2021003392A (es) Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados.
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
EP3770604A3 (en) Flow cytometry method for evaluating biological material for unassociated virus-size particles of influenza virus viral type
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
ZA202403393B (en) Synthetic chimeric poxviruses
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MX394775B (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
MX394778B (es) Método para la producción de circovirus porcino y vacunas pcv2.
CO2020000021A2 (es) Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.
MX2019007924A (es) Vacunas contra la influenza.
MX388635B (es) Vacunas atenuadas vivas del virus de la influenza equina
MX2020004151A (es) Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
MX378873B (es) Virus de sindrome reproductivo y respiratorio porcino (prrsv) que no ocurre de manera natural y metodos para usarlo.
KR101921384B9 (ko) 인플루엔자 바이러스 표면 단백질 헤마글루티닌 단량체를 포함하는 오소믹소바이러스에 대한 항원 조성물